文献速递预防保健、筛查与疫苗妇女保健老年与多病共存

新冠疫情期间美国乳腺癌筛查变化:真实世界健康记录数据分析

Breast Cancer Screening During the COVID-19 Pandemic in the United States: Results From Real-World Health Records Data.
PubMed 文献 · Ann Fam Med · 2024-01-01

本研究基于TriNetX真实世界健康记录,回顾性分析2017年1月至2022年2月期间符合乳腺癌筛查条件的女性队列。结果显示,2020年2月至4月月度筛查量暂时下降80.6%,至2020年6月回升至接近疫情前水平;但随访筛查率从疫情前的78.9%(95%CI,78.8%-79.0%)降至疫情期的77.7%(95%CI,77.6%-77.8%),多变量回归显示疫情期随访依从性更低(OR=0.86;0.86-0.87),且对65岁及以上女性和非西班牙裔「其他」种族女性影响更大。

要点

  • 2020年2月至4月乳腺癌月度筛查量暂时下降80.6%,6月回升至接近疫情前水平。
  • 随访筛查率由疫情前78.9%降至疫情期77.7%,疫情期随访依从性更低(OR=0.86)。
  • 65岁及以上女性和非西班牙裔「其他」种族女性受疫情影响更大。

核心结论

  • 新冠疫情对乳腺癌总体筛查量有暂时性负效应,对随访筛查有持续性负效应,并加剧了特定弱势群体随访依从性的差距。

研究设计与样本

  • 回顾性队列研究,使用TriNetX研究网络数据,纳入2017年1月1日至2022年2月28日期间符合乳腺癌筛查条件的女性1,186,669例。
  • 比较疫情前与疫情期随访筛查(前次筛查后24个月内应完成)的依从率,采用广义估计方程Logistic回归调整个体水平协变量。

主要发现

  • 月度筛查量从2020年2月至4月暂时下降80.6%,至2020年6月回升至接近疫情前水平。
  • 随访筛查率从疫情前78.9%(95%CI,78.8%-79.0%)降至疫情期77.7%(95%CI,77.6%-77.8%)。
  • 多变量回归显示疫情期随访依从性更低(OR=0.86;0.86-0.87)。
  • 疫情对65岁及以上女性和非西班牙裔「其他」种族(亚裔、美洲印第安人或阿拉斯加原住民、夏威夷原住民或其他太平洋岛民)女性的影响更大。

临床怎么用

  • 基层应关注疫情后乳腺癌随访筛查的持续性下降,主动识别并提醒应随访人群。
  • 对65岁及以上及特定种族弱势女性,需采取创新策略改善随访依从性、缩小健康差距。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The COVID-19 pandemic abruptly interrupted breast cancer screening, an essential preventive service in primary care. We aimed to evaluate the pandemic's impact on overall and follow-up breast cancer screening using real-world health records data. METHODS: We retrospectively analyzed a cohort of women eligible for breast cancer screening through the study period from January 1, 2017 to February 28, 2022 using TriNetX Research Network data. We examined the temporal trend of monthly screening volume throughout the study period and compared the rate of adherence to follow-up screening within 24 months after the previous screening when the follow-up screening was due in the pre-COVID period vs the COVID period. To account for multiple screenings in the longitudinal data, we applied a logistic regression model using generalized estimating equations with adjustment for individual-level covariates. RESULTS: Among 1,186,669 screening-eligible women, the monthly screening volume temporarily decreased by 80.6% from February to April 2020 and then rebounded to close to pre-COVID levels by June 2020. Yet, the follow-up screening rate decreased from 78.9% (95% CI, 78.8%-79.0%) in the pre-COVID period to 77.7% (95% CI, 77.6%-77.8%) in the COVID period. Multivariate regression analysis also showed a lower adherence to follow-up screening during the COVID period (odds ratio = 0.86; 0.86-0.87) and a greater pandemic impact among women aged 65 years and older and women of non-Hispanic "other" race (Asian, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander). CONCLUSIONS: The COVID-19 pandemic had a transient negative effect on breast cancer screening overall and a prolonged negative effect on follow-up screening. It also exacerbated gaps in adherence to follow-up screening, especially among certain vulnerable groups, requiring innovative strategies to address potential health disparities in primary care.

来源:Ann Fam Med,查看原文。版权归原作者所有。

引用

  1. Chung A, Chen Q, Curry W, et al. Breast Cancer Screening During the COVID-19 Pandemic in the United States: Results From Real-World Health Records Data. Ann Fam Med. 2024. PMID: 38806260. doi:10.1370/afm.3098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。